Table 2.
Comparative MICs of dalbavancin and other antimicrobials against selected Gram-positive and anaerobic organisms
| MIC90 range (μg/ml)* | ||||||
|---|---|---|---|---|---|---|
| Organism | Dalbavancin | Vancomycin | Linezolid | Teicoplanin | Quin/dalfo | Daptomycin |
| Staphylococcus aureus (25, 40, 42) | 0.06 | 1 | ≤ 2 | 2 | 0.5 | NA |
| Methicillin susceptible (25, 27, 41, 43, 44, 47, 48) | 0.06–0.5 | 1 | 1–4 | 2–4 | 0.25–0.5 | 0.5 |
| Methicillin resistant (25, 27, 41, 43, 44, 47, 48) | 0.06–1 | 1–4 | 0.5–8 | 2–4 | 0.5 | 0.5 |
| Glycopeptide intermediate (25, 39, 41) | 1–2 | 8 | 8–16 | 2 | 1 | NA |
| Staphylococcus coagulase negative (25, 40, 42) | 0.06–0.12 | 2 | 4–8 | 1–2 | 0.5 | NA |
| Methicillin susceptible† (25, 27, 43, 44, 47, 48) | 0.06–0.5 | 2 | 2–8 | 1–2 | 0.25–0.5 | 0.5 |
| Methicillin resistant† (25, 27, 43, 44, 47, 48) | 0.06–0.5 | 2–4 | 2–16 | 1–2 | 0.5–1 | 0.5 |
| Vancomycin non-susceptible (25) | 1 | 8 | > 32 | 2 | 0.5 | NA |
| Teicoplanin resistant (39, 45) | 0.25 | 2 | NA | 1 | 1 | NA |
| Staphylococcus epidermidis | ||||||
| Methicillin susceptible (27, 41) | 0.25–0.5 | 1–2 | 8 | NA | NA | NA |
| Methicillin resistant (27, 41) | 0.25 | 2–4 | 16 | NA | NA | NA |
| Staphylococcus haemolyticus | ||||||
| Methicillin susceptible (27) | 0.13 | 2 | 32 | NA | NA | 2 |
| Methicillin resistant (27) | 0.5 | 4 | 32 | NA | NA | NA |
| Streptococcus pneumoniae (25, 40, 42, 44, 46) | < 0.03–0.06 | 0.5 | 0.125 to ≤ 2 | 1–2 | < 0.5–1 | NA |
| Penicillin susceptible (25, 27, 48) | 0.03–0.06 | 0.5 | 0.06 | 1 | 0.5 | NA |
| Penicillin non-susceptible‡ (25, 27, 38, 48) | ≤ 0.016–0.03 | 0.5 | 0.06 | 1 | 0.5–1 | NA |
| Streptococcus pyogenes (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
| Erythromycin susceptible (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
| Erythromycin resistant (25) | 0.015 | 0.5 | 0.06 | 1 | ≤ 0.12 | NA |
| Viridans group streptococci (25, 40, 42, 44) | 0.016–0.03 | 1 | ≤ 2 | 1 | 0.5–1 | NA |
| Penicillin susceptible (25, 48) | 0.03 | 1 | 0.06 | 1 | 1 | NA |
| Penicillin non-susceptible (25, 48) | 0.03 | 0.5–1 | 0.12 | 1 | 1 | NA |
| Erythromycin susceptible (25) | 0.03 | 1 | 0.06 | 1 | 1 | NA |
| Erythromycin resistant (25) | 0.03 | 1 | 0.12 | 1 | 1 | NA |
| β-Haemolytic streptococci (25, 40, 42, 44, 48) | 0.015–0.06 | 0.5 | ≤ 2 | 1 | 0.5 | NA |
| Streptococcus agalactiae (25) | 0.015 | 0.5 | 0.12 | 1 | 0.25 | NA |
| Enterococcus spp. (40, 42) | 0.12–16 | 2 to > 16 | ≤ 2 to > 16 | 2 | > 2 | NA |
| Vancomycin susceptible (44) | 0.5 | 2 | 0.5 | NA | > 8 | NA |
| Vancomycin resistant (44) | 32 | > 16 | > 16 | NA | > 8 | NA |
| vanA resistant (27, 38) | 32 to > 128 | > 128 | > 128 | NA | NA | NA |
| vanB resistant (27) | 0.12–1 | 128 | ≤ 2 | 2 | 8 | NA |
| Enterococcus faecalis | ||||||
| Vancomycin susceptible (48) | 0.06 | NA | 0.5 | 2 | > 8 | NA |
| Vancomycin resistant (38, 48) | 32 | NA | > 16 | 2 | > 8 | NA |
| Enterococcus faecium | ||||||
| Vancomycin susceptible (48) | 0.12 | NA | 0.5 | 2 | 2 | NA |
| Vancomycin resistant (38, 48) | 32 | NA | > 16 | 2 | 1 | NA |
| Quin/dalfo resistant (38) | 0.12§–8¶ | NA | NA | 2 | NA | NA |
| Actinomyces spp. (28) | 0.5 | 1 | NA | 1 | 0.25 | 16 |
| Bacillus spp. (44) | 0.25 | 1 | 2 | NA | 2 | NA |
| Clostridium spp. (28) | 0.5 | 2 | NA | 4 | 0.5 | 8 |
| Clostridium difficile (28) | 0.25 | 2 | NA | 8 | 4 | 2 |
| Clostridium perfringens(28) | 0.125 | 0.5 | NA | 2 | 0.5 | 1 |
| Corynebacterium spp.(28, 44, 48) | ≤ 0.03–0.5 | 0.5–1 | 0.5 | 1 | 0.5–1 | 8 |
| Corynebacterium jeikeium (28) | 0.5 | 0.5 | NA | 0.5 | 0.5 | 0.25 |
| Lactobacillus spp. (48) | > 32 | > 32 | NA | 8 | 2 | > 32 |
| Listeria spp. (40) | 0.06 | NA | NA | NA | NA | NA |
| Peptostreptococcus spp. (28) | 0.25 | 0.5 | NA | 2 | 0.5 | 1 |
| Propionibacterium spp. (28) | 0.5 | 1 | NA | 1 | 0.2 | 16 |
Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60.
MIC90 range based on MIC90 values reported in different studies that compared dalbavancin with at least one of the comparator agents.
Data from Ref. (27) includes other coagulase-negative staphylococci, but do not include Staphylococcus epidermidis and Staphylococcus haemolyticus.
Includes penicillin-non-susceptible, penicillin-intermediate and penicillin-resistant isolates.
vanA negative isolates.
vanA positive isolates. MICs, minimum inhibitory concentrations; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant enterococci possessing the vanA gene.